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Objectives: This study was designed to evaluate the usefulness of assessing subgenual anterior 
cingulate cortex (sACC) volume reduction by magnetic resonance imaging (MRI) as an objective 
  auxiliary means of diagnosis of depression. The study was additionally designed to analyze the 
association of sACC volume reduction with the effectiveness of treatments for depression and 
other diseases presenting with similar symptoms, and to examine the possibility of using sACC 
volume reduction in the distinction between depression and bipolar disorder and determining 
optimum medication for these conditions.
Methods: Three-dimensional T1-weighted sagittal images, taken with Achieva 1.5T NOVA 
(Philips), were analyzed with VSRAD plus® to evaluate a reduction in sACC volume. The find-
ing from this analysis was compared with the clinical data, including the longitudinal course 
follow-up data based on the treatment algorithm.
Subjects: The study involved 88 patients aged over 54 who received MRI during 2010, ie, 71 
patients with major depressive disorder (MDD), 11 patients bipolar disorder, and 6 patients in 
whom the initial diagnosis (MDD) was later modified. Thirty-three normal individuals served 
as controls.
Results: sACC volume reduction was noted in 66 of the 71 patients receiving treatment of 
MDD, with sensitivity of 93%, specificity of 85%, and accuracy of 90%. In the 66 patients 
diagnosed as having MDD and exhibiting sACC volume reduction, the disease showed remis-
sion in response to treatment with antidepressants, but medication needed to be continued after 
achievement of remission. In cases initially diagnosed as having MDD but not exhibiting sACC 
volume reduction, the necessity of modifying the diagnosis was considered. Typical cases of 
bipolar disorder did not exhibit sACC volume reduction.
Conclusion: That patients receiving treatment of MDD often showed reduction in sACC 
volume suggests the usefulness of this parameter as an objective auxiliary means of diagnosis 
for MDD.
Keywords: depression,  subgenual anterior cingulate cortex (sACC), MRI, VSRAD, neuroimaging
Introduction
Depression is a disease difficult to diagnose, because it needs to be distinguished 
from various other diseases for the following reasons: 1) depression is sometimes 
accompanied by seasonal affective disorder, obsessive-compulsive disorder, or post-
traumatic stress disorder; 2) depression sometimes presents with symptoms similar 
to early symptoms of schizophrenia; and 3) depression occasionally appears at the 
early stage of dementia in elderly people. Failure to diagnose and treat depression International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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appropriately can result in unfortunate outcomes, leading 
to suicide in worst cases. Dropout from medical treatment 
is also seen among patients with depression, for reasons 
such as adverse reactions at early stages of antidepressant 
therapy or failure to establish a satisfactory doctor–patient 
  relationship. The absence of a reliable test assisting the 
diagnosis and treatment of depression is considered to be one 
of the major factors responsible for failure in establishment 
of a satisfactory doctor–patient relationship. At present, the 
diagnosis of depression is based on assessing the patient’s 
experience and behavior by means of interview and compar-
ing the interview findings with diagnostic criteria such as the 
Diagnostic and Statistical Manual of Mental Disorders-IV 
(DSM-IV). DSM-IV classification of psychiatric disorders 
is based on symptomatological findings, rather than on the 
pathophysiology or the mechanism for pathogenesis. In other 
words, depression is now diagnosed as a group of disorders 
which in nature involve varying features. For this reason, 
depression diagnosed in this way is composed of a mixture 
of diverse features, making it difficult to identify a feature 
specific to depression.
Chronological evaluation of the efficacy used for treat-
ment of depression and the choice of drugs for treatment 
of this disease also face similar limitations. Objective data 
such as biological indicators measured by laboratory tests 
are never used for such purposes. Lack of an established 
biological indicator of depression tends to reduce the moti-
vation of patients towards treatment and to make it difficult 
for physicians to have common recognition about treatment 
of this disease, thus serving as one of the factors responsible 
for interruption of treatment.
Depression has conventionally been viewed as repeating 
cycles of multiple phases and showing alleviation towards 
normal condition in response to treatment. In clinical prac-
tice, however, there are cases of depression where treatment 
with antidepressants and sleeping pills cannot be completed 
in much time even after alleviation of the disease phase or 
cases where cognitive function does not return to the pre-
disease level. Many depressed patients with poor prognosis 
respond poorly to both drug therapy and nondrug therapy (eg, 
cognitive behavioral therapy), which makes physicians feel 
limited in their management despite attempts to take adequate 
measures. How to deal with these cases is a difficult issue for 
physicians involved in clinical care of depression.
In recent years, the strategy for diagnosis of psychiatric 
diseases has been undergoing modifications following 
advances in diagnostic imaging and molecular biology. In 
cases of bipolar disorder, involvement of mitochondrial 
dysfunction and stress-induced reactions of endoplasmic 
reticulum has been reported. Patients with depression have 
been reported to show changes (often decrease) in grey 
matter volume of the anterior cingulated cortex, amygdala, 
hippocampus, and prefrontal area. Pezawas et al1 reported 
that the presence of S-type serotonin transporter gene pro-
moter affects intrauterine brain development, causing volume 
reduction of the subgenual anterior cingulated cortex (sACC). 
Since that report, the association between the brain area sACC 
and depression has been attracting close attention.
This paper describes our attempt at longitudinal and cross-
sectional research of the volume-reduced brain areas in patients 
with depression through whole brain analysis using a magnetic 
resonance imaging (MRI) system equipped with a Voxel-based 
Specific Regional analysis system for Alzheimer’s Disease   
(VSRAD plus®), a freeware computer program developed by 
Matsuda et al,2 as a means of diagnosing disorders associated 
with early Alzheimer dementia. The authors show that patients 
receiving treatment of major depressive disorder (MDD) have 
volume reduction more frequently in sACC than in the other 
regions (amygdala, hippocampus, and prefrontal area) and 
propose that checking for sACC volume reduction is useful 
as an objective auxiliary means of diagnosing MDD.
Objectives
The objectives of this study are 3-fold. Firstly, we evaluate 
the usefulness of VSRAD as an objective auxiliary means of 
diagnosing depression through analyzing the clinical data of 
depressed patients over 10 years with the findings of sACC 
atrophy (sACC volume reduction) as measured with MRI 
VSRAD. Secondly, we evaluate the association of the pres-
ence/absence of sACC volume reduction with the effective-
ness of medication for depression or diseases presenting with 
similar symptoms through analysis of the longitudinal course 
of treatment based on a drug treatment algorithm. Thirdly, we 
examine the possibility of utilizing sACC volume reduction 
data to distinguish between depression and bipolar disorder 
(often needed during clinical practice) and in selection of 
optimum medication for these diseases.
Subjects
During the 6-year period from 2001 to 2006, the authors 
accepted and managed 2652 patients as inpatients, including 
those referred from psychiatrists working in other medical 
facilities in Okinawa Prefecture, providing inpatient care in 
parallel with care for other patients. During the subsequent International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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4-year period (2007–2010), the authors provided only 
  outpatient care. Of the patients managed during this 10-year 
period, those able to receive MRI during 2010 and aged over 
54 (because the database for healthy individuals in VSRAD 
covered individuals aged between 54 and 86) were adopted 
as subjects of this study. (This study was made with adequate 
consideration to keep anonymity of individual patients and 
to avoid disclosure of personal information. Consent to this 
report has been obtained from all patients involved).
In total, 88 patients were enrolled to this study,   including 
71 patients diagnosed as having MDD according to the 
DSM-IV diagnostic criteria, aged over 54 and receiving anti-
depressant therapy, 11 patients diagnosed as having bipolar 
disorder according to the DSM-IV diagnostic criteria, and 
6 patients in whom the initial diagnosis (MDD) was later 
  modified. In view of the features of VARAD which cov-
ers elderly individuals as well, the following patients were 
excluded from this study: 1) patients in whom dementia 
developed after onset of depression, 2) patients in whom the 
management period was not long enough to allow definite 
diagnosis, and 3) patients unable to be followed at our facility 
due to a change to other medical facilities.
The 71 patients with MDD (12 males and 59 females) 
were aged between 54 and 82 years (mean: 65.4 ± 6.5). 
  Complication by anxiety disorder or panic disorder was seen 
in 31 (44%) of these 71 patients with MDD. The 11 patients 
with bipolar disorder (2 males and 9 females) were aged 
between 54 and 72 (mean 62.7 ± 4.8). The 6 patients in whom 
the initial diagnosis was later modified (5 males and 1 female) 
were aged between 55 and 76 years (mean 66.5 ± 5.2). For 
comparison with the MDD group, a healthy control group 
was examined in the study. The healthy control group was 
composed of 33 individuals who had no history of MDD 
and received MRI to rule out organic disease suspected for 
some reason (7 males and 26 females aged between 54 and 
84 years, with a mean age of 63.3 ± 5.7) (Table 1).
Evaluation of the 71 patients with MDD on the basis of 
the drug treatment algorithm yielded the following results. 
The duration of illness was 8 to 12 months on average. The 
treatment period ranged from 5 months to 10 years. HAM-D 
(Hamilton’s Rating Scale for Depression) value ranged 
from 10 to 30 (mean 17.8 ± 3.0). Age at onset of MDD was 
61.2 ± 6.9 years. Age at the time of evaluation was 54 to 
63 years in 33 cases, 64 to 73 years in 25 cases, and .74 
years in 13 cases. When the duration of illness was divided 
into 5   categories, it was ,6 months in none, .6 months, 
and ,1 year in 9 cases, .1 year and ,3 years in 24 cases, .3 
years and ,6 years in 19 cases and .6 years in 19 cases. 
When the treatment period was divided into 5 categories, it 
was ,6 months in 6 cases, .6 months and ,1 year in 15 
cases, .1 year and ,3 years in 20 cases, .3 years and ,6 
years in 21 cases, and .6 years in 9 cases. The disease severity 
score according to HAM-D classification was ,13 in 7 cases, 
14 to 18 in 39 cases, 19 to 22 in 15 cases, and .23 in 10 cases. 
The drug prescribed at the time of MRI was selective serotonin 
reuptake inhibitors (SSRI) in 61 cases, serotonin and norepi-
nephrine reuptake inhibitors (SNRI) in 9 cases, noradrenergic 
and specific serotonergic antidepressants (mirtazapine) in 
5 cases, sulpiride in 3 cases, tricyclic antidepressant in 2 cases, 
and tetracyclic antidepressant in 1 case (including some cases 
receiving 2 or more drugs at a time).
For 25 (35%) of the 71 patients with MDD, the prescribed 
drug was at the maintenance dose level (the antidepressant 
dose level kept at a certain level for 1 year or longer) at the 
time of MRI. The disease was in the phase of remission 
(HAM-D score ,7) in 35 (49%) of the 71 patients at the 
time of MRI. Thus, half of all patients with MDD received 
MRI when the disease had alleviated.
Methods
VSRAD used in the present study to assess volume reduction 
in local brain grey matter is a free computer program designed 
to evaluate relative local brain volume of individual patients 
through comparison of visual information from MRI with the 
brain image database for healthy individuals by means of voxel-
based morphometry (VBM). With this program, the 3D-T1 
weighted image of the entire brain, taken with a 1.5-Tesla 
MRI device, is processed with SPM2 (Statistical Parametric 
Mapping, 2002 Edition) to isolate grey matter, followed by 
automated statistical analysis of grey matter density in units 
of voxel for the entire brain based on anatomical standardiza-
tion (not involving any hypothesis). For statistical analysis in 
comparison to the image database for healthy individuals, Z 
score (the magnitude of grey matter density’s discrepancy, 
n × standard deviation (SD), in individual patients from the 
mean for healthy individuals) is calculated for each brain 
region, using the average image and SD contained in the image 
database. The results of analysis are displayed as a colored scale 
map on the standard brain. The database for healthy individu-
als includes 40 Japanese males and 40 Japanese females aged 
between 54 and 86 years (70.2 ± 7.3).
In the present study, 3-dimensional T1-weighted sagittal 
images were taken with an Achieve 1.5T NOVA (Philips) 
under the following setting: FOV 240, matrix 256 × 256, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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slice thickness 1 mm, 160 slices, TR 9.3 msec, TE 4.6 msec, 
flip angle 10 degrees. The obtained visual data were analyzed 
on a PC, with the program VSRAD plus®. The Z score map 
obtained was checked for the presence/absence of colored 
area, which indicates volume reduction (attenuation of signal 
density in the grey matter) within the regions of interest. 
On the brain image thus obtained, the areas showing vol-
ume reduction by Z score $2 or more are designed to be 
colored blue. We visually checked the presence/absence of 
sACC volume reduction on the images with ROI (region of 
interest) set in the sACC. The finding as to presence/absence 
of volume reduction in sACC, hippocampus, amygdale, and 
prefrontal area of individual patients was compared with the 
clinical data from the same patients for the previous 10-year 
period. Chi-square for independence test was employed for 
statistical analysis.
Results
Association between MDD and sAcc 
volume reduction (Figure 1)
Of the 71 patients with MDD, 66 showed sACC volume 
reduction. Volume reduction in hippocampus, prefrontal 
area, and amygdala was noted in 35, 20, and 21 patients, 
respectively. sACC volume reduction as an indicator for the 
diagnosis of MDD had a sensitivity of 93%, specificity of 
85%, and accuracy of 90%. In the MDD group, sACC volume 
Table 1 clinical characteristics of the total sample (n = 121)
Characteristics Mean (SD) H U χ2 df P value
MDD BD DC HC
sample, no. 71 11 6 33
sex, no.
  Male 12 2 5 7 14.56 3 0.002
  Female 59 9 1 26
Age, y 65.37 (6.55) 62.73 (4.79) 66.50 (5.17) 63.36 (5.69) 2.95 3 0.4
complicationa 31
hAMD, point 17.8(3.0) 17.5 (1.33) 214.5 0.49
  –13 7 0
  14–18 39 4
  19–22 15 2
  23– 10 0
Age at onset, y 61.20 (6.86) 55.46 (5.32) 61.5 (5.67) 5.04 2 0.08
  –53 0 5 1
  54–63 33 5 1
  64–73 25 1 4
  74– 13 0 0
Duration of illness, y 4.41 (2.34) 7.27 (1.70) 5.33 (3.11) 9.22 2 0.01
  –0.5 0 0 0
  0.5–1 9 0 0
  1–3 24 0 1
  3–6 19 2 3
  6– 19 9 2
Duration of treatment, y 2.80 (1.99) 7.27 (1.70) 4.23 (2.51) 20.43 2 P , 0.001
  –0.5 6 0 0
  0.5–1 15 0 1
  1–3 20 0 2
  3–6 21 2 1
  6– 9 9 2
Drug use (include combined use)
  ssrI 61
  sNrI 9
  NassA 5
  sulpiride 3
  Tricycle anti-dep 2
  Tetracycle ant-dep 1
Note: acomplication, 31 patients had MDD and anxiety disorder or panic disorder.
Abbreviations: anti-dep, antidepressant; BD, bipolar disorder; Dc, diagnostic change case; H, Kruskal–Wallis nonparametric multiple sample test; hAMD, hamilton’s rating 
Scale for Depression; HC, healthy controls; MDD, major depression disorder; NaSSA, noradrenergic and specific serotonergic antidepressant; SNRI, serotonin noradrenaline 
reuptake inhibitor; ssrI, selective serotonin reuptake inhibitor; U, Mann–Whitney nonparametric 2-sample test. International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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reduction was noted more frequently than volume reduction 
in any other region of the brain (Table 2).
Of the 11 patients with bipolar disorder, 6 showed sACC 
volume reduction. sACC volume reduction was not seen 
in any of the 6 patients in whom the initial diagnosis was 
later modified. Of the 33 normal controls, 5 showed sACC 
volume reduction.
The MDD group showed significant sACC volume 
reduction measured by MRI compared with the normal 
control group, regardless of gender, age, duration of illness, 
treatment period, length of time before remission, disease 
severity, accompanying physical disease, type of antidepres-
sant used, drug dose level, or dosing period (Table 3). Of the 
71 patients with MDD, 35 showed volume reduction in the 
hippocampus, 20 showed volume reduction in the prefrontal 
area, and 21 showed volume reduction in the amygdale.
Association between sAcc volume 
reduction and diagnosis/treatment of MDD
For the course of treatment and its efficacy, the patients who 
received drug therapy after diagnosis of MDD in accordance 
with DSM-IV diagnostic criteria could be divided into the 
following 2 groups depending on the presence/absence 
of sACC volume reduction, and each group had different 
characteristics:
1.  Group showing sACC volume reduction (66/71 cases)
2.  Group without sACC volume reduction (5/71 cases)
The characteristic findings from each group can be sum-
marized as:
1.  Group showing sACC volume reduction (66 cases): 
A characteristic of the course of treatment in this group 
was favorable responses to antidepressant treatment such 
as SNRI or SSRI seen in many cases. In this group, the 
length of time until remission of symptoms (50% or more 
decrease in HAMD score) following the start of antide-
pressant treatment was short and was 3 months in 43 
(65%) of the 66 cases. The disease alleviated rapidly after 
antidepressants inappropriate for individual cases were 
determined. However, all cases required maintenance 
antidepressant therapy even after remission. Discontinua-
tion of antidepressant intake at the patient’s own discretion 
was seen in 15 cases. In all of these 15 cases, symptoms 
relapsed. Thus, in cases showing sACC volume reduction, 
treatment with antidepressants resulted in remission of 
the disease, but continuation of drug therapy was needed 
after remission.
2.  Group without sACC volume reduction (5/71 cases): 
In this group, all patients treated with antidepressants 
showed remission of the disease within 6 months. Of these 
patients, 3 had severe depression (HAMD score .24) 
and had been receiving inpatient care, and 2 patients had 
been taking a rest from their work for 1 month or more. 
Of the 3 patients having received inpatient care, 1 is now 
followed with fluvoxamine (an SSRI) at the maintenance 
dose (25 mg) and 2 are now followed with paroxetine at 
a dose of 10 mg, and all are leading a favorable course. 
For the 2 patients who took a rest from their work, anti-
depressant therapy has been completed, and they are now 
followed with sleeping pills alone.
As of December 2010, all 5 of these patients had restored 
social activity. Three (age 55, 58, and 69 years) were   working, 
Left medial Right medial
2.0
A
B
6.0
Figure 1 A) Z-score maps of a 58-year-old woman with major depressive disorder 
(MDD). B) A 60-year-old normal woman (control). The color scale for Z score is 
shown in the upper left of the figure. Presented in color if Z score is .2. In the 
patient with MDD (A) the subgenual cingulate gyrus and the surrounding region are 
colored blue, indicating volume reduction. In the normal control (B), no colored 
region, reflecting volume reduction, is visible.
Table 2 reduction of regional brain volume
Location MDD (n = 71) BD (n = 11) DC (n = 6) HC (n = 33)
subgenual anterior cingulate cortex 66 (93.0%) 6 (54.5%) 0 (0%) 5 (15.2%)
Amygdala 21 (29.6%) 2 (18.2%) 0 (0%) 2 (6.1%)
hippocampus 35 (49.3%) 4 (36.4%) 0 (0%) 2 (6.1%)
Prefrontal cortex 20 (28.2%) 2 (18.2%) 1 (16.7%) 1 (3.0%)
Abbreviations: BD, bipolar disorder; Dc, diagnostic change case; hc, healthy controls; MDD, major depression disorder.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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1 (age 66 years) was a housewife, and the other (age 79 years) 
was taking care of her husband at home as a housewife. All 
5 of these patients retained cognitive function and were 
visiting the hospital once monthly while driving a car by 
themselves.
Association between sAcc volume 
reduction and modification of initial 
diagnosis of MDD
Among the patients studied, there were 6 cases in which 
drug therapy with antidepressants after diagnosis of MDD in 
accordance with DSM-IV diagnostic criteria was   ineffective 
and failed to result in remission. In all of these 6 cases, 
MRI VSRAD revealed sACC volume reduction. The initial 
diagnosis was later modified in all these cases. The courses 
followed by these 6 cases can be summarized as:
One case of sleep apnea syndrome complicated  
by hypertension
Case 1: A 71-year-old male. Previously treated with SNRI for 
3 years at another facility, but referred to our facility because 
of poor responses. At our facility, the diagnosis was modified, 
and CPAP therapy (continuous positive airway pressure for 
treatment of apnea) and blood control were performed, and 
resulted in alleviation of psychiatric symptoms and gradual 
reduction of antidepressant dose level to zero.
Two cases markedly responding to pregabalin 
treatment
Case 2: A 64-year-old male. Failed to respond to SNRI 
treatment, but responded markedly to pregabalin (a product 
marketed in Japan since July 2010) 1 week after the start of 
treatment. After its dose level was increased to 300 mg, all 
antidepressants were discontinued. The patient had been com-
plaining of chronic lower back pain for the past 20 years. The 
lower back pain had not alleviated and the patient had been 
referred from an orthopedic clinic to our facility as a case of 
depression (the disease had not alleviated until recently).
Case 3: A 76-year-old male. Failed to respond to SNRI, but 
showed alleviation rapidly within 1 week after the start of 
pregabalin treatment. After its dose level was increased to 
450 mg, all antidepressants were discontinued gradually. Pain 
due to cervical herniation had not alleviated after surgery. 
Patient was later diagnosed as having depression on the 
basis of sleeplessness and depressed mood, and treatment 
was started.
Both cases failed to satisfy the diagnostic criteria for 
fibrous myalgia and had been treated as cases of chronic pain 
complicated by depression.
One case later developing Parkinson’s disease
Case 4: A 67-year-old male. Received SSRI therapy for 
depression but the disease did not alleviate. Later, the disease 
advanced into Parkinson’s disease, which responded well to 
anti-Parkinsonian drugs.
Two cases with economic issues and personal 
relationship, and environmental problems
Case 5: A 55-year-old male. Case 6: A 64-year-old female. In 
both cases, the priority was to resolve economic issues and 
personal relationship and environmental problems. At early 
Table  3  relationship  between  the  characteristics  and  the 
reduction of sAcc volume in MDD patients
Reduction   
of sACC
χ2 df P value
+ -
sex
  Male 10 2 2.04 1 0.97
  Female 56 3
Age, y
  54–63 31 2 0.092 2 0.96
  64–73 23 2
  74–82 12 1
site
  right 61 10 2.24 1 0.13
  Left 54 17
hAMD, point
  –13 7 0 9.94 3 0.02
  14–18 37 2
  19–22 15 0
  23– 7 3
Duration of illness, y
  0.5–1 9 0 1.69 3 0.64
  1–3 23 1
  3–6 17 2
  6– 17 2
Duration of treatment, y
  –0.5 6 0 3.62 4 0.46
  0.5–1 15 0
  1–3 19 1
  3–6 18 3
  6– 8 1
Drug use (include combined use)
  ssrI 56 5 1.06 5 0.96
  sNrI 9 0
  NassA 5 0
  sulpiride 3 0
  Tricycle anti-dep 2 0
  Tetracycle ant-dep 1 0
Abbreviations:  anti-dep,  antidepressant;  hAMD,  hamilton’s  rating  scale  for 
Depression;  MDD,  major  depression  disorder;  NaSSA,  noradrenergic  and  specific 
serotonergic antidepressant; sAcc, subgenual anterior cingulate cortex; sNrI, serotonin 
noradrenaline reuptake inhibitor; ssrI, selective serotonin reuptake inhibitor.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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stages of treatment, antidepressants were   additionally used, 
but they were ineffective and discontinued.
In these 6 cases, the finding of lack of sACC volume 
reduction revealed by MRI VSRAD was very useful, serving 
as an objective finding contributing to reviewing whether or 
not the initial diagnosis of MDD was appropriate. In other 
words, sACC volume reduction was found to serve as an 
important indicator for careful review of possible error in 
the initial diagnosis, instead of maintaining the diagnosis 
of MDD, in cases in which antidepressant therapy for the 
initially diagnosed MDD does not result in alleviation.
Association between sAcc volume 
reduction and diagnosis/treatment  
of bipolar disorder
In all of the 11 cases with bipolar disorder diagnosed and 
treated in accordance with DSM-IV diagnostic criteria and 
subsequently followed with mood modulators, MRI was 
carried out 5 years or more after the start of treatment. The 
finding of sACC volume reduction was very useful in the 
management of these cases and, interestingly, it was consis-
tent with the clinical course.
For the course and efficacy of treatment, these cases 
could be divided into the following 2 groups depending on 
the presence/absence of sACC volume reduction, and each 
group had different characteristics:
1.  Group without sACC volume reduction (5/11 cases)
In all 5 of these cases, remission was maintained with 
mood modulators alone.
2.  Group showing sACC volume reduction (6/11 cases)
In some of these 6 cases, the depressed phase repeated 
cycles of remission and relapse, making treatment difficult 
and requiring hospitalization during the depressed phase. Con-
comitant use of antidepressants was needed in this group.
examples of sAcc volume reduction 
data in cases free of subjective symptoms
Among the normal controls showing sACC volume reduc-
tion, 1 case (56-year-old female) later required   sleeping pills. 
Detailed interview of this patient after acquisition of volume 
reduction data revealed difficulty in falling into sleep and 
experiencing fatigue. This case did not satisfy the criteria for 
diagnosis of MDD among the DSM-IV criteria and began 
to receive early intervention when HAMD score was 10. At 
present, this woman is receiving sleeping pills only and can 
continue working.
The cases presented above were cases aged .54 years, 
the age group selected in accordance with the range of age 
included in MRI VSRAD. Using a similar method, we 
  previously studied cases aged ,54 years (40 cases) and 
obtained findings similar to those presented in this paper. 
This paper was confined to reporting cases aged .54 years 
analyzed with VSRAD criteria.
Discussion
This study analyzed morphological abnormalities of the brain 
(sACC volume reduction) associated with depression and 
evaluated the usefulness of VSRAD (a technique of VBM 
for such abnormalities) as an auxiliary diagnostic means. 
To our knowledge, this is the first study involving clear-cut 
analysis of the longitudinal and cross-sectional correlation 
of depression to MRI VSRAD. sACC volume reduction did 
not correlate with age (.54 years), gender, disease severity, 
duration of illness, treatment period, type of drug used, or 
drug dose. sACC volume reduction remained to be seen even 
after remission (HAMD score ,7). The evaluation of the 
association between sACC volume reduction and validity of 
treatments for depression and other diseases presenting with 
similar symptoms revealed that that if MRI VSRAD is utilized 
as an auxiliary diagnostic means of diagnosis of depression, it 
enables the prediction of prognosis in the following way.
1.  In cases diagnosed as having MDD in accordance with 
DSM-IV diagnostic criteria and showing only sACC 
volume reduction, remission can be achieved by the 
use of antidepressants suitable for individual patients at 
appropriately adjusted doses, but continuation of antide-
pressant therapy at maintenance dose level will be needed 
after achievement of remission.
2.  In cases diagnosed as having MDD in accordance with 
DSM-IV diagnostic criteria, showing no sACC volume 
reduction and responding well to antidepressants, the 
dose of antidepressants can be gradually reduced to zero. 
In these cases, close follow-up as to possible bipolar 
episodes will be needed.
3.  In cases diagnosed as having MDD in accordance with 
DSM-IV diagnostic criteria, failing to show alleviation of 
symptoms and remission despite treatment and showing 
no sACC volume reduction, a finding of lack of sACC 
volume reduction is very useful when the initial diag-
nosis is reviewed fundamentally. The initial diagnosis 
is highly likely to be wrong in such cases, and review 
of the diagnosis is likely to enable prevention of errone-
ous diagnosis/treatment (repetition of usefulness dose 
increase or switching of antidepressants).
Numerous studies have reported abnormalities of the 
brain associated with depression. Neuroimaging studies of International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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MDD, conducted to date, pertained to analysis of changes in 
grey matter volume of hippocampus,3–8 amygdala,9–11 striate 
body,12 prefrontal area,13,14 and anterior cingulate cortex,15–21 
which are structures involved in the hypothamic–pituitary–
adrenocortical system function, emotion/cognition, and 
adjustments. Many of these studies revealed grey matter 
volume reduction in these areas.
The present study involved analysis of the association of 
volume reduction in sACC, hippocampus, prefrontal area, 
and amygdala with MDD, but the sensitivity and true posi-
tive rate were low for volume reduction in hippocampus, 
prefrontal area, or amygdala when used as an indicator of 
MDD (Table 2). This result may be explained as follows. 
With VSRAD, areas with Z score .2 (ie, areas with density 
differing by 2 × SD or more from the mean for normal data-
base) are depicted as volume-reduced areas. The sensitivity 
was markedly high for volume reduction in sACC, and this 
suggests that close attention should be paid to sACC when 
VSRAD is used.
The ACC, which contains sACC as a part, is a component 
of the cerebral cortex, and its anterior part forms the medial 
side of the frontal lobe (including Brodmann Area 24, 25, 
and 32). It is involved in cognitive function (attentiveness) 
and also in emotional responses as a part of the limbic system. 
In addition, ACC is involved also in dealing with pain and 
struggle. Among studies on sACC volume reduction, there 
is a report that ACC volume reduction was seen in all of 68 
cases with MDD and 88 cases with MDD accompanied by 
anxiety disorder, and that sACC was noted in patients having 
developed depression at age ,18 years.22
Among studies of brain function associated with sACC, 
using diagnostic imaging, there are studies during rest in 
patients with episodes of depression, demonstrating reduced 
cerebral blood flow and compromised metabolism in the 
anterior half of the cerebrum (particularly in the anterior 
part of cingulated cortex, subcallosal area, islet, orbital area, 
and mediodorsal–laterodorsal frontal area).23,24 Recently, 
many reports using functional MRI have been published, 
including a report showing that patients with depression 
have compromised function in the prefrontal area during 
implementation of a cognitive task, and hyperactivity of the 
limbic system (including the amygdala) during an emotional 
task.25 In   studies on depression-associated brain function 
by diagnostic imaging, close attention has been paid to the 
brain areas showing changes after treatment and brain areas 
showing abnormal blood flow or metabolism after treatment. 
  Generally, the reduction of cerebral blood flow and metabo-
lism seen in the dorsolateral prefrontal area of untreated 
patients with depression is mood-dependent and tends to 
normalize after remission of symptoms, while the cerebral 
blood flow and metabolism in the medial prefrontal area tends 
to remain reduced even after alleviation of depression. This 
indicates occasional discrepancy between symptoms and 
brain function rated by diagnostic imaging.26
The findings from the patients studied suggest that if 
patients receiving treatment of depression showed sACC 
volume reduction, they probably required continued drug 
treatments even after remission of the symptoms of depres-
sion. The results suggest that VSRAD may be used as a 
means of following the course of symptoms of depression, 
with a focus set at the sACC, and judging the necessity of 
antidepressants after remission.
The next question pertains to the mechanism for reduc-
tion in the volume of sACC. It is known that excessive 
stress destroys the cellular function of responding to stress, 
inducing apoptosis of the cells. If nerve cells are exposed to 
stress, they lose viability, possibly resulting in compromised 
brain function and onset of various neurological diseases. 
Thus, cells are known to undergo not only extermination 
due to physical damages and intense disorders (eg, caused 
by toxins) but also death arising from lack of proliferation 
signals or various stimuli. These types of cellular death are 
called programmed death or apoptosis of cells. It is unknown 
whether the sACC volume reduction observed in the present 
study reflected apoptosis of nerve cells or a decrease in glial 
cell volume. According to a recent report, sACC volume 
reduction is most likely to reflect decrease in nerve cell 
volume and glial cell density.27 Further studies are needed 
on this issue.
For bipolar disorder, the present study has demonstrated 
that patients with depression complicated by bipolar dis-
order and showing sACC volume reduction responded to 
antidepressants, which resulted in remission. In patients with 
bipolar disorder alone (the uncomplicated group), sACC 
volume reduction was absent. In other words, these results 
suggest that patients with uncomplicated bipolar disorder 
respond to treatment with mood modulators alone, while 
patients with depression complicated by bipolar disorder 
are expected to respond to combined mood modulator plus 
antidepressant therapy. This retrospective finding suggests 
that MRI VARAD may be useful when judging the necessity 
of combined use of antidepressants or continued combined 
use of antidepressants during the depressed phase of patients 
receiving treatment on the basis of the diagnosis of bipolar 
disorder. After our detection of the presence of an ACC vol-
ume reduction group among patients with bipolar disorder, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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a paradigm shift (treatment strategy based on awareness of the 
presence of bipolar disorder plus MDD cases) was useful in 
our clinical practice. MRI VSRAD will be also useful when 
treating cases diagnosed as having bipolar disorder if these 
cases show sACC volume reduction, in view of the possibility 
that these cases are actually in a drug-induced manic phase 
of depression following treatment with inappropriate antide-
pressants and they should be managed as cases of depression. 
Our conclusion at present is that the volume reduced area 
of sACC probably responds to antidepressants. Depression 
differs in disease characteristics from bipolar disease and it 
involves longitudinal changes of brain morphology. Brain 
sites possibly involved in bipolar disorder are diverse.28 For 
diagnostic imaging, there is a report that tractograms, yielded 
from tracing of the fibers of anterior thalamic radiation on 
diffusion tensor images, revealed reduced cross-sectional 
area of the anterior thalamic radiation, suggesting disturbed 
white matter between thalamus and anterior lobe at the 
bilateral anterior thalamic radiation as well as association of 
bilateral disturbance in nerve development with the patho-
genesis of bipolar disorder.29 Further studies on this topic 
are also desirable.
When treatments are selected and the prognosis is pre-
dicted, it is significant to define depression as “a condition 
involving sACC volume reduction and presenting with 
psychiatric symptoms”. That is, the volume reduction in this 
area serves as an indicator of vulnerability to stress. When 
dealing with patients showing sACC volume reduction and 
presenting with related psychiatric symptoms (sleepless-
ness, depressed mood, fatigue, and pain), it is advisable to 
consider the necessity of treatment with antidepressants on 
the basis of assessment of psychiatric symptoms through 
detailed interview. Instead of relying on the conventional 
ways of diagnosis and treatment based solely on the features 
of depression and bipolar disorder, it is desirable to adopt 
a basic stance by which some particular areas of the brain 
(eg, sACC) are assessed for anomaly (volume reduction) and 
treatments (antidepressants) to make up for the lost function 
are considered. If the view that antidepressants are effective 
in cases showing sACC volume reduction is endorsed, it will 
be very useful during clinical practice.
Open issues
The results from the present study do not allow us to read-
ily conclude that the absence of sACC volume reduction 
suggests antidepressants to be unnecessary. According to a 
report presented at the 28th Meeting of the Japanese Society 
for Magnetic Resonance in Medicine 2010, calculation of the 
hippocampal Z score with MRI VSRAD has been used as 
an auxiliary means of diagnosing dementia, despite concern 
that the spread of this technique could result in excessive 
reliance on numerical data (not combined with the original 
images) in diagnosis of dementia. This means that even when 
the usefulness of MRI as a means of diagnostic imaging is 
widely accepted, diagnosis of depression solely on the basis 
of MRI findings should be avoided. Clinicians need to deal 
with their patients in a modest and calm manner.
In future, more studies are awaited on the relationship 
between genes and sACC volume reduction:
1.  Regarding the validity of checking for sACC volume 
reduction in the diagnosis of depression in individuals 
aged .54 years, it is necessary to carry out large-scale 
studies at other medical facilities and research facilities. 
Clinical studies on a global scale are desirable.
2.  If attention is paid to sACC volume reduction at the time 
of diagnosis based on MRI during thorough brain checks, 
for example, it may be possible to identify high-risk indi-
viduals from the viewpoint of prevention of depression. 
Linkage between the psychiatric department and the brain 
diagnostic imaging department, among others, needs to 
be considered.
3.  If a computer program enabling application of reference 
normal images to younger generations (20s through 40s) 
is developed, it will also serve as an objective indicator of 
depression among young individuals. Nations with a high 
prevalence of depression among their young generations 
will lose vitality and may decline. Global utilization of 
simply and immediately applicable MRI VARAD will 
enable appropriate diagnosis and treatment of depression, 
covering all generations.
It is also important to analyze the phenotypes at various 
  levels (such as brain nerve circuits, brain function, brain struc-
ture, molecule/gene expression, gene polymorphism) and to 
attempt further classification of depression (a disease consisting 
of diverse conditions) and further evaluation of its features.
Conclusion
The present study has analyzed the potential of VSRAD as an 
auxiliary means of diagnosing depression in clinical cases.
By showing that sACC volume reduction was seen frequently 
among patients receiving treatment of MDD, the authors have 
demonstrated the usefulness of sACC volume reduction as 
an objective auxiliary means of diagnosing MDD and that 
depression differs in terms of disease characteristics from 
bipolar disease, which has the potential to involve longitu-
dinal changes of brain morphology.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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At present, studies with a molecular biology approach 
are being performed, involving measurement of genes and 
biomaterials associated with depression. Numerous reports 
of case of depression diagnosed using near-infrared spectros-
copy of brain function have been published. However, this 
kind of device has not become widespread in Japan. Even 
though positron emission tomography (PET), which visual-
izes glucose metabolism with radioisotopes, has been shown 
to be useful in evaluation of brain function and blood flow, 
the number of facilities equipped with devices for nuclear 
medicine is smaller than that of facilities equipped with MRI 
devices, and the cost of PET is higher than that of MRI. The 
number of MRI devices available for use is very large in Japan 
compared with many other countries, with more than 6000 
MRI devices in use in Japan. VSRAD can be characterized 
by its capability of visual and objective judgment as to the 
site of change and the extent of change even by physicians 
not well experienced with diagnostic imaging. It thus yields 
objective data about the condition of individual patients 
which can be shared between the physician and the patient 
or among physicians.
(Note: An anonymous reviewer has pointed out that 
Fabienne et al (2011) has demonstrated that conditions of 
corpus callosum are directly related to suicidality in older 
individuals. Thus far, we have not been able to obtain the 
paper because it has not been published yet. A similar 
argument is also made by Ballmaier et al.30 VSRAD is a 
software program that measures conditions of grey mater, 
thus examinations of corpus callosum are beyond the scope 
of this paper. Nevertheless, a software program capable of 
measuring conditions of white matter is currently under 
development, and further research is awaited).
The number of individuals who committed suicide in 
Japan has exceeded 30,000 per year every year since 1998, 
and depression is considered to be involved in 60% of all 
suicides. If more MRI devices in Japan are used to detect 
sACC volume reduction (an indicator of vulnerability to 
stress), MRI will be very effective in preventing suicide. 
This is because the combination of MRI and VSRAD is 
useful as an auxiliary means of diagnosis of depression, 
enabling automated detection of sACC volume reduction 
even by physicians of nonpsychiatric specialties, in addi-
tion to psychiatrists having received clinical training on 
depression, thus facilitating early detection of depression 
across the country. This will lead to prevention of suicide. 
Patients showing sACC volume reduction have the potential 
to respond to early intervention if they are observed as the 
risk factor group (vulnerable to stress) even when they are 
currently free of psychiatric symptoms. If MRI VSRAD can 
be introduced as a part of thorough brain checks to establish 
a system for detection of sACC volume reduction, it will 
facilitate early detection and treatment of depression. To 
conclude, we hope that this study will trigger dissemination 
of the awareness that the finding of sACC volume reduction 
as a sign of depression is useful as an auxiliary means for 
prevention of suicide and that data endorsing this view are 
collected on a global scale.
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